Daniel Pollyea, MD, MS, obtained his medical degree from the University of Chicago Pritzker School of Medicine, Chicago, IL, in 2003, followed by his residency in internal medicine. Dr Pollyea then completed his fellowship training in hematology and oncology at Stanford University, Stanford, CA, where he stayed to complete his master’s in epidemiology with a focus on biostatistics and clinical trial design.
Dr Pollyea is currently the Clinical Director of Leukemia Services at the University of Colorado, Denver, CO. Since his appointment as Clinical Director, he has served as the Principal Investigator of several early-phase clinical trials, receiving funding from the American Society of Hematology, the American Society of Clinical Oncology, and the Leukemia and Lymphoma Society.
Dr Pollyea is the recipient of various awards, namely the Chairman’s Quality of Life Award, Leukemia and Lymphoma Society Rocky Mountain Chapter (2018) and the Endowed Chair in Hematology Research, Robert H. Allen (2018).
Speaking on developmental therapeutics for myeloid malignancies
Dr Pollyea’s research focuses on the development of novel therapeutic strategies for myeloid malignancies like myelodysplastic syndromes (MDS) and acute myeloid leukemia (AML). Dr Pollyea is the Principal Investigator for several clinical trials, namely a Phase I clinical study of arsenic trioxide with cyclophosphamide in relapsed/refractory AML (NCT03318016) and a Phase II study of venetoclax and azacitidine in AML (NCT03573024).